drugset
drugset / Trial / NCT04049552

RAPA-Keloid Study of Keloid Regression

NCT04049552 ↗

Phase 0 Completed 4 enrolled The University of Texas Health Science Center at San Antonio
Non-randomizedSingle-groupSingle-blindTreatment

Summary

1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2. To test safety of product and feasibility of conduct for future clinical trial

Timeline

Start
2020-01-24
Primary completion
2020-08-24
Completion
2021-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 8 % Topical

Indications

keloid